Table 2.
Target tumor characteristics and responses Tumor characteristics and final response after vaccination course. The two non-target BCCs on patient one were not followed during the study. Patient nine had three biopsy verified BCC at diagnosis, but one could not be found at start of vaccinations. High Background indicates that the samples had high background which precluded evaluation of response to IO103.
| ID | Target Tumor Location | Target Tumor Type (Longest Diameter, mm) | Target, Clinical Response | Target, Change (%) | ELISPOT Response to IO103 in PBMCs | ELISPOT Response to IO103 in SKILs |
|---|---|---|---|---|---|---|
| 1 | Shoulder | sBCC (20) | NC | −25 | ** | High Background |
| 2 | Chest | sBCC (10) | PR | −30 | ** | 0 |
| 3 | Upper arm | nBCC (25) | NC | −20 | ** | ** |
| 4 | Lower leg | sBCC (51) | NC | −5.9 | ** | ** |
| 5 | Back | sBCC (19) | NC | −5.3 | * | High Background |
| 6 | Chest | nBCC (18) | NC | 0 | * | NA |
| 7 | Back | sBCC (22) | NC | −9.1 | ** | NA |
| 8 | Shoulder | nBCC (14) | NC | 0 | 0 | * |
| 9 | Back | sBCC (20) | NC | 0 | ** | ** |
| 10 | Shoulder | nBCC (15) | PR | −33 | ** | ** |
CR: complete response, nBCC: nodular BCC, NA: not available, NC: no change, PR: partial response, sBCC: superficial BCC, *: DFRx1, **: DFRx2.